During the COVID-19 pandemic, new cases in the U.S. have repeatedly risen and dropped dramatically.
A new research paper led by the Imperial College London, published in the peer-reviewed journal nature communications, finds the following:.
Flow Pharma, Inc., a San Francisco Bay Area biotechnology company developing the FlowVax™ peptide vaccine platform technology, today announced the publication of an article describing research performed at the University of Texas Medical Branch at Galveston (UTMB)
In December 2019, a novel coronavirus, termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was identified as the cause of pneumonia with severe respiratory distress and outbreaks in Wuhan, China.